2-甲基-2-(4-硝基苯氧基)丙酸 | 17431-97-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-2-(4-硝基苯氧基)丙酸
• 英文名称: 2-(4-nitrophenoxy)-2-methylpropanoic acid
• 英文别名: 2-methyl-2-(4-nitrophenoxy)propanoic acid；α-(4-nitro-phenoxy)-isobutyric acid；α-(4-Nitro-phenoxy)-isobuttersaeure；2-(4-Nitrophenyloxy)-2-methylpropionsaeure；2-(4-Nitrophenoxy)-2-methylpropionic acid；2-Methyl-2-(4-nitrophenoxy)propionsaeure
• CAS: 17431-97-9
• 化学式: C₁₀H₁₁NO₅
• mdl: MFCD03422282
• 分子量: 225.201
• InChiKey: ZGQMZVWPCVHENS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-甲基-2-(4-硝基苯氧基)丙酸 在 iron hydroxide 作用下， 生成 2-(4-氨基苯氧基)-2-甲基丙酸
  参考文献：
  名称：

  Joensson, Acta Chemica Scandinavica (1947), 1953, vol. 7, p. 596,599

  摘要：

  DOI：
• 作为产物：
  描述：

  4-nitrophenol sodium salt 生成 2-甲基-2-(4-硝基苯氧基)丙酸
  参考文献：
  名称：

  Bischoff, Chemische Berichte, 1900, vol. 33, p. 1605

  摘要：

  DOI：

文献信息

• [EN] ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS<br/>[FR] COMPOSÉS ÉTHER D'ARYLE ET ÉTHER D'HÉTÉROARYLE EN TANT QUE MODULATEURS DE ROR GAMMA
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2015159233A1

  公开（公告）日：2015-10-22

  The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R2, R3, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

  本公开涉及式(I)的化合物及其药用盐，其中环A、环B、R、R2、R3、n和p如本文所定义，这些化合物作为视黄酸相关孤儿受体γt（RORγt）的调节剂具有活性。这些化合物可以预防、抑制或抑制RORγt的作用，因此在治疗RORγt介导的疾病、疾病、综合症或症状方面具有用处，例如疼痛、炎症、慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、结肠炎、多发性硬化、牛皮癣、神经退行性疾病和癌症。
• Synthesis and Preliminary Antihyperlipidaemic Activities Evaluation of Andrographolide Derivatives
  作者：Bin Wang、Chunlei Tang、Yaodan Han、Ruzhou Guo、Hai Qian、Wenlong Huang

  DOI：10.2174/157340612800493629

  日期：2012.4.26

  Recent studies indicated that andrographolide was a potential antihyperlipidaemic therapeutic agent. In the paper, the synthesis of a series of andrographolide derivatives was described and their antihyperlipidaemic activities were evaluated in vivo. As compared with TG, TC, HDL-C and LDL-C concentrations, some of the derivatives exhibited better antihyperlipidaemic effects than positive control atromide. Therein, compound 6i, which was the most potent compound, could serve as a new lead for further development of antihyperlipidaemic agents.

  最近的研究表明，穿心莲内酯是一种潜在的抗高脂血症治疗药物。本文描述了一系列穿心莲内酯衍生物的合成，并评估了它们在体内的抗高脂血症活性。与甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）和低密度脂蛋白胆固醇（LDL-C）浓度相比，一些衍生物表现出的抗高脂血症效果优于阳性对照药物阿托洛伐。值得注意的是，化合物6i是最有效的化合物，可以作为进一步开发抗高脂血症药物的新先导。
• Synthesis, In Vitro, In Vivo and In Silico Antidiabetic Bioassays of 4-Nitro(thio)phenoxyisobutyric Acids Acting as Unexpected PPARγ Modulators: An In Combo Study
  作者：Blanca Colin-Lozano、Héctor Torres-Gomez、Sergio Hidalgo-Figueroa、Fabiola Chávez-Silva、Samuel Estrada-Soto、Julio Cesar Almanza-Pérez、Gabriel Navarrete-Vazquez

  DOI：10.3390/ph15010102

  日期：——

  Four isobutyric acids (two nitro and two acetamido derivatives) were prepared in two steps and characterized using spectral analysis. The mRNA concentrations of PPARγ and GLUT-4 (two proteins documented as key diabetes targets) were increased by 3T3-L1 adipocytes treated with compounds 1–4, but an absence of in vitro expression of PPARα was observed. Docking and molecular dynamics studies revealed the plausible interaction between the synthesized compounds and PPARγ. In vivo studies established that compounds 1–4 have antihyperglycemic modes of action associated with insulin sensitization. Nitrocompound 2 was the most promising of the series, being orally active, and one of multiple modes of action could be selective PPARγ modulation due to its extra anchoring with Gln-286. In conclusion, we demonstrated that nitrocompound 2 showed strong in vitro and in vivo effects and can be considered as an experimental antidiabetic candidate.

  四个异丁酸（两个硝基和两个乙酰胺衍生物）通过两步制备，并使用光谱分析进行表征。用化合物1-4处理的3T3-L1脂肪细胞的PPARγ和GLUT-4的mRNA浓度增加，但观察到PPARα在体外表达的缺失。对接和分子动力学研究揭示了合成化合物与PPARγ之间的可能相互作用。体内研究表明，化合物1-4具有与胰岛素敏感性相关的抗高血糖作用。硝基化合物2是该系列中最有前途的，口服活性，可能的作用模式之一是选择性PPARγ调节，因为它与Gln-286有额外的锚定。总之，我们证明了硝基化合物2在体内和体外都表现出强烈的效果，可以被视为一种实验性抗糖尿病候选药物。
• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Li Hui

  公开号：US20090041786A1

  公开（公告）日：2009-02-12

  The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

  这项发明涵盖了具有I-V公式的化合物以及使用这些化合物在治疗需要调节JAK通路或抑制JAK激酶，特别是JAK3的情况下可能具有治疗作用的组合物和方法。
• Hexahydronaphthalene ester derivatives, their preparation and their
  申请人：Sankyo Company, Limited

  公开号：US05491167A1

  公开（公告）日：1996-02-13

  Compounds of formula (I): ##STR1## and their salts and esters have the ability to inhibit the synthesis of cholesterol, and can thus be used for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.

  式(I)的化合物：##STR1##及其盐和酯具有抑制胆固醇合成的能力，因此可用于治疗和预防高胆固醇血症和各种心脏疾病。